Androgen Receptor (AR-V7 specific) Antibody [F19P24]

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 IHC1:250

Application
WB, IHC

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
68 kDa 80 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Positive Control	22Rv1 (1% SDS Hot lysis)
Negative Control	Human prostate cancer tissue; Human liver tissue; Human hepatocellular carcinoma tissue; Human fetal liver; T-47D cells; PC-3 cells; LNCaP cells; 22Rv1 (RIPA lysis method)

Datasheet & SDS

Biological Description

Specificity
Androgen Receptor (AR-V7 specific) Antibody [F19P24] detects endogenous levels of total Androgen Receptor (AR-V7 specific) protein.

Clone
F19P24

Synonym(s)
AR; NR3C4; Androgen receptor; Dihydrotestosterone receptor; Nuclear receptor subfamily 3 group C member 4

Background
Androgen Receptor variant 7 (AR-V7) is a constitutively active splice variant of the full-length androgen receptor, generated by alternative splicing that retains the N-terminal transactivation domain, the DNA-binding domain with two zinc fingers, and the hinge region, but lacks the ligand-binding domain, which is replaced by a unique 16-amino-acid cryptic exon at the C-terminus. This structural alteration allows AR-V7 to enter the nucleus independently of androgen binding and importin-α/β pathways, exhibit high intranuclear mobility, form homodimers through the DNA-binding domain, and bind DNA to activate a distinct set of target genes. In castration-resistant prostate cancer, AR-V7 drives androgen receptor signaling even in low-androgen conditions by activating genes involved in proliferation and survival, such as EDN2, TMPRSS2, and KLK3, while also regulating isoform-specific alternative splicing events and contributing to therapy resistance against anti-androgens. AR-V7 promotes tumor progression and poor clinical outcomes, and its detection in circulating tumor cells serves as a biomarker for stratifying patients.

Background

Androgen Receptor variant 7 (AR-V7) is a constitutively active splice variant of the full-length androgen receptor, generated by alternative splicing that retains the N-terminal transactivation domain, the DNA-binding domain with two zinc fingers, and the hinge region, but lacks the ligand-binding domain, which is replaced by a unique 16-amino-acid cryptic exon at the C-terminus. This structural alteration allows AR-V7 to enter the nucleus independently of androgen binding and importin-α/β pathways, exhibit high intranuclear mobility, form homodimers through the DNA-binding domain, and bind DNA to activate a distinct set of target genes. In castration-resistant prostate cancer, AR-V7 drives androgen receptor signaling even in low-androgen conditions by activating genes involved in proliferation and survival, such as EDN2, TMPRSS2, and KLK3, while also regulating isoform-specific alternative splicing events and contributing to therapy resistance against anti-androgens. AR-V7 promotes tumor progression and poor clinical outcomes, and its detection in circulating tumor cells serves as a biomarker for stratifying patients.

References
https://pubmed.ncbi.nlm.nih.gov/32989253/ https://pubmed.ncbi.nlm.nih.gov/20823238/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%